{"id":"NCT00551642","sponsor":"Mallinckrodt","briefTitle":"Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies","officialTitle":"The Effects of Nitric Oxide for Inhalation on the Development of Chronic Lung Disease in Pre-term Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05-29","primaryCompletion":"2008-03-16","completion":"2015-07-17","firstPosted":"2007-10-31","resultsPosted":"2010-10-18","lastUpdate":"2021-02-05"},"enrollment":800,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Lung Disease"],"interventions":[{"type":"DRUG","name":"Nitric oxide","otherNames":["INO maxÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Inhaled Nitric Oxide (INO)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and efficacy of inhaled nitric oxide to reduce the risk of chronic lung disease in pre-term infants with respiratory distress, and to assess the long-term effects of the therapy on the development of these children over 7 years of clinical follow-up.","primaryOutcome":{"measure":"Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress","timeFrame":"21 days","effectByArm":[{"arm":"Inhaled Nitric Oxide (INO)","deltaMin":258,"sd":null},{"arm":"Placebo","deltaMin":262,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.7340"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":35,"countries":["Belgium","Finland","France","Germany","Italy","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["28046032","23940237","20655106"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":170,"n":395},"commonTop":["Anaemia","Patent ductus arteriosus","Hyperbilirubinaemia","Jaundice","Hyperglycaemia"]}}